WO2016144704A3 - Heterocyclic autotaxin inhibitor compounds - Google Patents

Heterocyclic autotaxin inhibitor compounds Download PDF

Info

Publication number
WO2016144704A3
WO2016144704A3 PCT/US2016/020733 US2016020733W WO2016144704A3 WO 2016144704 A3 WO2016144704 A3 WO 2016144704A3 US 2016020733 W US2016020733 W US 2016020733W WO 2016144704 A3 WO2016144704 A3 WO 2016144704A3
Authority
WO
WIPO (PCT)
Prior art keywords
heterocyclic
inhibitor compounds
compounds
autotaxin inhibitor
autotaxin
Prior art date
Application number
PCT/US2016/020733
Other languages
French (fr)
Other versions
WO2016144704A2 (en
Inventor
John Howard Hutchinson
David Lonergan
Original Assignee
Pharmakea, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmakea, Inc. filed Critical Pharmakea, Inc.
Publication of WO2016144704A2 publication Critical patent/WO2016144704A2/en
Publication of WO2016144704A3 publication Critical patent/WO2016144704A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
PCT/US2016/020733 2015-03-11 2016-03-03 Heterocyclic autotaxin inhibitor compounds WO2016144704A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562131744P 2015-03-11 2015-03-11
US62/131,744 2015-03-11

Publications (2)

Publication Number Publication Date
WO2016144704A2 WO2016144704A2 (en) 2016-09-15
WO2016144704A3 true WO2016144704A3 (en) 2016-11-03

Family

ID=56879699

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/020733 WO2016144704A2 (en) 2015-03-11 2016-03-03 Heterocyclic autotaxin inhibitor compounds

Country Status (1)

Country Link
WO (1) WO2016144704A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018215070A1 (en) * 2017-05-24 2018-11-29 Johann Wolfgang Goethe-Universität Frankfurt am Main Dual modulators of farnesoid x receptor and soluble epoxide hydrolase
WO2021053234A1 (en) * 2019-09-19 2021-03-25 Johann Wolfgang Goethe-Universität Frankfurt am Main Compounds and compositions for treating kidney disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090054508A1 (en) * 2005-01-27 2009-02-26 Kyowa Hakko Kogyo Co., Ltd. Igf-1r inhibitor
US7514463B2 (en) * 2004-08-20 2009-04-07 University Of Kansas Lonidamine analogues and their use in male contraception and cancer treatment
WO2012024620A2 (en) * 2010-08-20 2012-02-23 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
US8293781B2 (en) * 2007-03-29 2012-10-23 Daiichi Sankyo Company, Limited Indole derivatives having cPLA2 inhibiting activity and applications and production methods of the same
WO2012166415A1 (en) * 2011-05-27 2012-12-06 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514463B2 (en) * 2004-08-20 2009-04-07 University Of Kansas Lonidamine analogues and their use in male contraception and cancer treatment
US20090054508A1 (en) * 2005-01-27 2009-02-26 Kyowa Hakko Kogyo Co., Ltd. Igf-1r inhibitor
US8293781B2 (en) * 2007-03-29 2012-10-23 Daiichi Sankyo Company, Limited Indole derivatives having cPLA2 inhibiting activity and applications and production methods of the same
WO2012024620A2 (en) * 2010-08-20 2012-02-23 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
WO2012166415A1 (en) * 2011-05-27 2012-12-06 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE Chemical Abstract 9 August 2001 (2001-08-09), retrieved from STN Database accession no. 350834-11-6 *

Also Published As

Publication number Publication date
WO2016144704A2 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
WO2015077503A8 (en) Autotaxin inhibitor compounds
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2017095944A8 (en) Methods and compositions relating to chondrisomes from blood products
WO2016118951A3 (en) Heterocyclic itk inhibitors for treating inflammation and cancer
SA518400356B1 (en) Arginase inhibitors and their therapeutic applications
IL255509B (en) Compounds as ccr2 modulators, pharmaceutical compositions comprising same and their use for the treatment of diseases
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
EP3490603A4 (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
MX2016012262A (en) Cenicriviroc for the treatment of fibrosis.
MX2022007436A (en) Autotaxin inhibitors and uses thereof.
MX2017009417A (en) Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof.
PH12017501095A1 (en) Piperidine derivatives as hdac1/2 inhibitors
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
EP3528852A4 (en) Methods and compositions for the treatment of fabry disease
WO2016004413A3 (en) Gls1 inhibitors for treating disease
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2017014456A (en) Therapeutic uses of l-4-chlorokynurenine.
WO2016073771A3 (en) Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors
MX2017010277A (en) Cenicriviroc for the treatment of fibrosis.
EP3570670A4 (en) Compositions and methods for treating lysosomal storage diseases and disorders
WO2016144704A3 (en) Heterocyclic autotaxin inhibitor compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16762187

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16762187

Country of ref document: EP

Kind code of ref document: A2